Latest Period
Q2 2026
Security Snapshot
Cytek Biosciences, Inc. - Common Stock, par value $0.001 per share (CTKB) Institutional Ownership
CUSIP: 23285D109
13F Institutional Holders and Ownership History from Q3 2021 to Q2 2026
Institutions Reporting
152
Shares (Excl. Options)
81,518,376
Price
$4.43
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- CTKB on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 81,518,376
- Total 13F value
- $361,053,622
- Portfolio coverage rank
- 0%
- Share change
- -3,642,164
- Value change
- -$15,871,916
- Number of holders
- 152
- Shares outstanding
- 129,694,583
- SEC-reported price per share
- $4.43
- Insider filing price
- $4.43
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CTKB - Cytek Biosciences, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 23285D109.
- 152 institutions reported positions in Q2 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 163 to 152 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $371,768,715 to $361,053,622.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 152 institutions filings for Q2 2026.
Security key
23285D109
Latest holder period
Q2 2026
13F holders
152
13D/G owners
5
CIK / CUSIP context first
Open Q2 2026 holders
CTKB full holder history
Cytek Biosciences, Inc. SEC filings
Cytek Biosciences, Inc. company facts
Cytek Biosciences, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 23285D109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
CTKB
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 7.2% | -45% | $41,443,907 | -$31,782,305 | 9,356,551 | -43% | BlackRock, Inc. | 30 Jun 2026 |
| MILLENNIUM MANAGEMENT LLC | 7.2% | +18% | $41,367,384 | +$6,490,437 | 9,338,010 | +19% | Millennium Management LLC | 30 Jun 2026 |
| Boston Partners | 5.9% | $33,823,692 | 7,635,145 | Boston Partners | 30 Jun 2026 | |||
| Topline Capital Management, LLC | 5.3% | $28,140,515 | 6,780,847 | Topline Capital Management, LLC | 25 Sep 2025 | |||
| BROWN CAPITAL MANAGEMENT LLC | 3.9% | -33% | $17,204,316 | -$8,695,650 | 4,958,016 | -34% | Brown Capital Management, LLC | 30 Sep 2025 |
As of 30 Jun 2026, 152 institutional investors reported holding 81,518,376 shares of Cytek Biosciences, Inc. - Common Stock, par value $0.001 per share (CTKB). This represents 63% of the company’s total 129,694,583 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
55%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7.4% | 9,578,643 | -44% | 0% | $42,433,388 |
| MILLENNIUM MANAGEMENT LLC | 7.2% | 9,338,010 | +48% | 0.03% | $41,367,384 |
| Boston Partners | 5.9% | 7,660,943 | +32% | 0.03% | $33,942,877 |
| HHLR ADVISORS, LTD. | 5.1% | 6,657,030 | 0% | 3.5% | $29,490,643 |
| Topline Capital Management, LLC | 4.8% | 6,283,450 | -11% | 7.2% | $27,835,684 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.8% | 4,939,597 | +3.7% | 0% | $21,882,415 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4% | 3,059,573 | +8% | 0% | $13,557,155 |
| DIMENSIONAL FUND ADVISORS LP | 2% | 2,616,257 | -1.8% | 0% | $11,589,081 |
| STATE STREET CORP | 2% | 2,566,121 | -38% | 0% | $11,367,916 |
| GOLDMAN SACHS GROUP INC | 1.7% | 2,167,515 | -7.6% | 0% | $9,602,092 |
| ROYCE & ASSOCIATES LP | 1.6% | 2,081,579 | +27% | 0.07% | $9,221,395 |
| Russell Investments Group, Ltd. | 1.2% | 1,511,315 | +11% | 0.01% | $6,695,120 |
| ACADIAN ASSET MANAGEMENT LLC | 1.1% | 1,376,048 | +245% | 0.01% | $6,089,000 |
| BANK OF AMERICA CORP /DE/ | 1% | 1,315,332 | +30% | 0% | $5,826,921 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.88% | 1,141,592 | -51% | 0% | $5,057,253 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.83% | 1,073,253 | -2.8% | 0% | $4,754,511 |
| NORTHERN TRUST CORP | 0.77% | 1,003,294 | -0.19% | 0% | $4,444,592 |
| HRT FINANCIAL LP | 0.77% | 997,769 | +141% | 0.01% | $4,420,000 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 0.75% | 973,833 | +204% | 0% | $4,314,080 |
| JANE STREET GROUP, LLC | 0.7% | 906,162 | 0% | $4,014,298 | |
| TUDOR INVESTMENT CORP ET AL | 0.65% | 837,913 | +161% | 0.02% | $3,711,955 |
| AQR CAPITAL MANAGEMENT LLC | 0.63% | 813,971 | -11% | 0% | $3,605,891 |
| VANGUARD FIDUCIARY TRUST CO | 0.57% | 740,662 | +3.3% | 0% | $3,281,133 |
| CITADEL ADVISORS LLC | 0.56% | 721,470 | +53% | 0% | $3,196,112 |
| MORGAN STANLEY | 0.54% | 701,792 | -59% | 0% | $3,108,937 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
20
Latest
Q2 2026
Rows shown
1-20 of 20
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 81,518,376 | $361,053,622 | -$15,871,916 | $4.43 | 152 |
| 2026 Q1 | 85,067,527 | $371,768,715 | +$11,134,292 | $4.37 | 163 |
| 2025 Q4 | 82,036,336 | $414,284,117 | +$11,052,705 | $5.05 | 155 |
| 2025 Q3 | 79,927,508 | $277,365,376 | +$1,944,386 | $3.47 | 150 |
| 2025 Q2 | 79,443,660 | $270,126,999 | +$5,595,600 | $3.40 | 156 |
| 2025 Q1 | 77,562,435 | $311,007,504 | -$4,129,971 | $4.01 | 159 |
| 2024 Q4 | 77,254,066 | $501,381,338 | +$11,940,410 | $6.49 | 150 |
| 2024 Q3 | 74,960,438 | $415,264,156 | -$14,542,700 | $5.54 | 134 |
| 2024 Q2 | 76,158,342 | $424,969,676 | -$33,289,478 | $5.58 | 126 |
| 2024 Q1 | 80,524,601 | $540,295,292 | +$11,110,651 | $6.71 | 119 |
| 2023 Q4 | 78,933,920 | $719,883,797 | +$17,961,713 | $9.12 | 101 |
| 2023 Q3 | 77,486,686 | $427,726,918 | -$3,527,385 | $5.52 | 106 |
| 2023 Q2 | 77,036,054 | $657,934,234 | +$69,958,551 | $8.54 | 100 |
| 2023 Q1 | 68,508,151 | $629,603,408 | +$39,123,355 | $9.19 | 100 |
| 2022 Q4 | 64,201,674 | $655,512,030 | +$29,671,547 | $10.21 | 100 |
| 2022 Q3 | 61,170,760 | $900,430,367 | +$128,781,199 | $14.72 | 87 |
| 2022 Q2 | 52,912,941 | $567,776,021 | +$56,303,644 | $10.73 | 81 |
| 2022 Q1 | 47,712,980 | $514,520,453 | +$122,459,757 | $10.78 | 72 |
| 2021 Q4 | 35,038,930 | $571,924,873 | -$4,872,187 | $16.32 | 51 |
| 2021 Q3 | 34,351,929 | $744,420,532 | +$744,420,530 | $21.41 | 53 |